Auvi-Q (Epinephrine) Patent Expiration, LOE Window & CMS Spending

Auvi-Q (Epinephrine) by Kaleo: FDA Orange Book LOE 2037-12-21, 1 AB generics, $7.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorKaleo
FDA Application & PathwayN201739 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2037-12-21
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$7.9M
2024 Medicare Part D Spend$713K
2024 Medicaid Spend$7.1M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel